Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aptevo Therapeutics (APVO) Non-Current Deffered Revenue (2016 - 2017)

Aptevo Therapeutics (APVO) has disclosed Non-Current Deffered Revenue for 3 consecutive years, with $2.8 million as the latest value for Q2 2017.

  • Quarterly Non-Current Deffered Revenue fell 16.29% to $2.8 million in Q2 2017 from the year-ago period, while the trailing twelve-month figure was $2.8 million through Jun 2017, down 16.29% year-over-year, with the annual reading at $2.9 million for FY2016, 12.72% down from the prior year.
  • Non-Current Deffered Revenue hit $2.8 million in Q2 2017 for Aptevo Therapeutics, roughly flat from $2.8 million in the prior quarter.
  • In the past five years, Non-Current Deffered Revenue ranged from a high of $3.3 million in Q2 2016 to a low of $2.8 million in Q2 2017.
  • Historically, Non-Current Deffered Revenue has averaged $3.0 million across 3 years, with a median of $3.0 million in 2016.
  • Biggest five-year swings in Non-Current Deffered Revenue: decreased 12.72% in 2016 and later fell 16.29% in 2017.
  • Year by year, Non-Current Deffered Revenue stood at $3.3 million in 2015, then fell by 12.72% to $2.9 million in 2016, then fell by 3.45% to $2.8 million in 2017.
  • Business Quant data shows Non-Current Deffered Revenue for APVO at $2.8 million in Q2 2017, $2.8 million in Q1 2017, and $2.9 million in Q4 2016.